Investors

On this page, Investors will find announcements, news, detailed financial reports, and links to useful tools regarding Bioventix plc. This site contains key corporate, financial and shareholder information for Bioventix plc. The information disclosed is for the purposes of AIM Rule 26. Further details of company information relating to compliance with AIM Rule 26 can be found here.

We announced our results for the financial year ended 30 June 2023 on Monday 30 October.

£ 0 M

Revenue increased by 9% to £12.82 million

(2022: £11.72 million)

£ 0 M

PBT up by 9% to £10.13m

(2022: £9.28m)

  • Loading stock data...

An overview of our half year results with key financials and the future outlook.

Bioventix Financial Overview

Turnover

£12.816 Million

Profit before tax

£10.033 Million

Basic earnings per share

160.63 pence

2024 Diary Dates

Mon 25th March

Release of the unaudited accounts for the ½ year from 1st July 2023 to 31st December 2023

Mon 28th October

Release of the audited accounts for the full year from 1st July 2023 to 30th June 2024

Thu 5th December

Bioventix plc AGM, 2pm

Buying Shares

Bioventix’s shares are traded on the Alternative Investment Market with the symbol BVXP. Click the link to go to our AIM page.

Cavendish Capital Markets Limited (Cavendish) are our Nominated Advisor and Stock Broker. If you wish to buy shares in Bioventix plc please contact your stockbroker.

You can also get further information from the London Stock Exchange AIM website.

Announcements

Director/PDMR Shareholding

29 January 2024

Bioventix plc (“Bioventix” or “the Company”) Director Dealing   Bioventix plc (BVXP), a UK company specialising in the development…

Director/PDMR Shareholding

28 November 2023

Bioventix plc   (“Bioventix” or “the Company”)   Director Dealing    Bioventix plc (BVXP), a UK company specialising in the development…

Holding(s) in Company

16 November 2023

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Accounts & AGM

Annual Report 2023 Notice of AGM & Proxy Forms

10 November 2023

Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for…

PRELIMINARY RESULTS FOR YEAR TO 30 JUNE 2023

30 October 2023

Director’s report and financial statements for the year ended 30th June 2023. To download this report as a PDF…

Unaudited Interim Results For The Six Months Ended 31 December 2022

3 April 2023

Interim Report and Financial Statements for the 6 months to 31 December 2022   To download this report as…

Aim Compliance

This site contains key corporate, financial and shareholder information for Bioventix plc. The information disclosed is for the purposes of AIM Rule 26.

Last updated 29 January 2024

Bioventix plc is subject to the UK City Code on Takeovers and Mergers.

Company Information

Address

7 Roman’s Business Park, East Street, Farnham, Surrey GU9 7SX

Company Number

4923945

VAT Number

GB 822 6186 34

Country of Incorporation/Company Operation

United Kingdom

Registered Office

Cargil Management Services Ltd
27-28 Eastcastle Street, London W1W 8DH

Key Business

Healthcare, Diagnostics

Key Products

Sheep Monoclonal Antibodies

Constitutional Documents

Articles of Association
AIM Admission Document

Directors and Advisers

Directors

Ian James Nicholson, Non-Executive Chairman

Peter John Harrison, Chief Executive Officer

Bruce Edward Heath Hiscock, Chief Finance Officer

Nicholas John McCooke, Non-Executive Director

Joanne Patra Pisani, Non-Executive Director

All of: Bioventix Plc, 7 Romans Business Park, East Street, Farnham, Surrey, GU9 7SX

Nominated Adviser & Broker

Cavendish Capital Markets Limited (Cavendish)
1 Bartholomew Cl, London EC1A 7BL

Reporting Accountant & Auditor

Kreston Reeves LLP

2nd Floor 168 Shoreditch High Street, London, E1 6RA

Registrars

Share Registrars Limited, The Courtyard, 17 West Street, Farnham GU9 7DR

Committees and Members

Remuneration Committee

Nick McCooke (Chair)
Ian Nicholson
Jo Pisani

Audit Committee

Jo Pisani (Chair)
Ian Nicholson
Nick McCooke

Nomination Committee

Nick McCooke (Chair)
Ian Nicholson
Jo Pisani

Share Information

Primary Trading Exchange

London Stock Exchange AIM

Other exchanges or trading platforms where shares traded

None

Share Identification Ticker

AIM:BVXP

ISIN

GB00B4QVDF07

SEDOL

B4QVDF0

Share Type and Value

Ordinary Shares £0.05 each

Number of Securities in Issue

5,209,333

Percentage of shares not in public hands

48%

Restrictions on transfer of shares

None

Significant Shareholdings

Sanford DeLand

12.8%

Gresham House

11.1%

Liontrust

11.0%

Peter Harrison

6.9%

Hargreaves Lansdown Stockbrokers

6.6%

Rathbone Investment Management (inc. Investec)

6.2%

Danske Bank

2.9%

Hargreaves Lansdown Fund Managers

2.3%

Edentree Investment Management

2.1%

Charles Stanley

1.9%

Schroder Investment Management

1.3%

Corporate Governance

Bioventix plc is committed to maintaining high standards of corporate governance and has adopted the QCA Corporate Governance Code (“the Code”). The Board has reviewed the corporate governance framework that Bioventix plc operates and considers it to be effective and proportional to the size, risks, complexity and operations of Bioventix plc and reflective of the company’s culture and values. Details of how Bioventix plc complies with the Code can be found in the Corporate Governance Statement contained on pages 36-56 of the Annual Report.

Terms of Reference for Bioventix plc Board Committees are as follows:

Audit Committee

Remuneration Committee

Nomination Committee